

Rolf Hilgenfeld

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/1844871/publications.pdf>

Version: 2024-02-01

96
papers

13,698
citations

50276

46
h-index

37204

96
g-index

113
all docs

113
docs citations

113
times ranked

15292
citing authors

#	ARTICLE	IF	CITATIONS
1	Crystal structure of SARS-CoV-2 main protease provides a basis for design of improved Î±-ketoamide inhibitors. <i>Science</i> , 2020, 368, 409-412.	12.6	2,527
2	Coronavirus Main Proteinase (3CLpro) Structure: Basis for Design of Anti-SARS Drugs. <i>Science</i> , 2003, 300, 1763-1767.	12.6	1,514
3	The crystal structures of severe acute respiratory syndrome virus main protease and its complex with an inhibitor. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2003, 100, 13190-13195.	7.1	879
4	Crystal structure of active elongation factor Tu reveals major domain rearrangements. <i>Nature</i> , 1993, 365, 126-132.	27.8	569
5	Design of Wide-Spectrum Inhibitors Targeting Coronavirus Main Proteases. <i>PLoS Biology</i> , 2005, 3, e324.	5.6	547
6	Nsp3 of coronaviruses: Structures and functions of a large multi-domain protein. <i>Antiviral Research</i> , 2018, 149, 58-74.	4.1	542
7	Structure of coronavirus main proteinase reveals combination of a chymotrypsin fold with an extra alpha-helical domain. <i>EMBO Journal</i> , 2002, 21, 3213-3224.	7.8	538
8	From <scp>SARS</scp> to <scp>MERS</scp>: crystallographic studies on coronaviral proteases enable antiviral drug design. <i>FEBS Journal</i> , 2014, 281, 4085-4096.	4.7	537
9	Î±-Ketoamides as Broad-Spectrum Inhibitors of Coronavirus and Enterovirus Replication: Structure-Based Design, Synthesis, and Activity Assessment. <i>Journal of Medicinal Chemistry</i> , 2020, 63, 4562-4578.	6.4	437
10	The SARS-Coronavirus-Host Interactome: Identification of Cyclophilins as Target for Pan-Coronavirus Inhibitors. <i>PLoS Pathogens</i> , 2011, 7, e1002331.	4.7	367
11	Accessory proteins of SARS-CoV and other coronaviruses. <i>Antiviral Research</i> , 2014, 109, 97-109.	4.1	339
12	From SARS to MERS: 10 years of research on highly pathogenic human coronaviruses. <i>Antiviral Research</i> , 2013, 100, 286-295.	4.1	292
13	Crystal structure of Zika virus NS2B-NS3 protease in complex with a boronate inhibitor. <i>Science</i> , 2016, 353, 503-505.	12.6	285
14	X-ray screening identifies active site and allosteric inhibitors of SARS-CoV-2 main protease. <i>Science</i> , 2021, 372, 642-646.	12.6	240
15	SARS-CoV-2 Mpro inhibitors and activity-based probes for patient-sample imaging. <i>Nature Chemical Biology</i> , 2021, 17, 222-228.	8.0	215
16	pH-dependent Conformational Flexibility of the SARS-CoV Main Proteinase (Mpro) Dimer: Molecular Dynamics Simulations and Multiple X-ray Structure Analyses. <i>Journal of Molecular Biology</i> , 2005, 354, 25-40.	4.2	175
17	p53 down-regulates SARS coronavirus replication and is targeted by the SARS-unique domain and PL^{pro} via E3 ubiquitin ligase RCHY1. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2016, 113, E5192-201.	7.1	172
18	The SARS-CoV-2 main protease Mpro causes microvascular brain pathology by cleaving NEMO in brain endothelial cells. <i>Nature Neuroscience</i> , 2021, 24, 1522-1533.	14.8	164

#	ARTICLE	IF	CITATIONS
19	The SARS-Unique Domain (SUD) of SARS Coronavirus Contains Two Macrodomains That Bind G-Quadruplexes. <i>PLoS Pathogens</i> , 2009, 5, e1000428.	4.7	156
20	Two non-prolinecispptide bonds may be important for factor XIII function. <i>FEBS Letters</i> , 1998, 423, 291-296.	2.8	138
21	Peptide aldehyde inhibitors challenge the substrate specificity of the SARS-coronavirus main protease. <i>Antiviral Research</i> , 2011, 92, 204-212.	4.1	112
22	A G-quadruplex-binding macrodomain within the "SARS-unique domain" is essential for the activity of the SARS-coronavirus replication-transcription complex. <i>Virology</i> , 2015, 484, 313-322.	2.4	112
23	Crystal structure of Mip, a prolyl isomerase from <i>Legionella pneumophila</i> . <i>Nature Structural Biology</i> , 2001, 8, 779-783.	9.7	105
24	Peptide-Boronic Acid Inhibitors of Flaviviral Proteases: Medicinal Chemistry and Structural Biology. <i>Journal of Medicinal Chemistry</i> , 2017, 60, 511-516.	6.4	105
25	Nucleocapsid protein of SARS coronavirus tightly binds to human cyclophilin A. <i>Biochemical and Biophysical Research Communications</i> , 2004, 321, 557-565.	2.1	104
26	3C Protease of Enterovirus 68: Structure-Based Design of Michael Acceptor Inhibitors and Their Broad-Spectrum Antiviral Effects against Picornaviruses. <i>Journal of Virology</i> , 2013, 87, 4339-4351.	3.4	91
27	Processing of the SARS-CoV pp1a/ab nsp7-10 region. <i>Biochemical Journal</i> , 2020, 477, 1009-1019.	3.7	90
28	The Evolution of Insulin Glargine and its Continuing Contribution to Diabetes Care. <i>Drugs</i> , 2014, 74, 911-927.	10.9	81
29	A Structural View of the Inactivation of the SARS Coronavirus Main Proteinase by Benzotriazole Esters. <i>Chemistry and Biology</i> , 2008, 15, 597-606.	6.0	79
30	Molecular mechanisms of severe acute respiratory syndrome (SARS). <i>Respiratory Research</i> , 2005, 6, 8.	3.6	78
31	Picornavirus non-structural proteins as targets for new anti-virals with broad activity. <i>Antiviral Research</i> , 2011, 89, 204-218.	4.1	76
32	Crystal structure of the papain-like protease of MERS coronavirus reveals unusual, potentially druggable active-site features. <i>Antiviral Research</i> , 2014, 109, 72-82.	4.1	74
33	Nonstructural Proteins 7 and 8 of Feline Coronavirus Form a 2:1 Heterotrimer That Exhibits Primer-Independent RNA Polymerase Activity. <i>Journal of Virology</i> , 2012, 86, 4444-4454.	3.4	73
34	Structure and Cleavage Specificity of the Chymotrypsin-Like Serine Protease (3CLSP _{nsp4}) of Porcine Reproductive and Respiratory Syndrome Virus (PRRSV). <i>Journal of Molecular Biology</i> , 2009, 392, 977-993.	4.2	66
35	A common core for binding single-stranded DNA: structural comparison of the single-stranded DNA-binding proteins (SSB) from <i>E. coli</i> and human mitochondria. <i>FEBS Letters</i> , 1997, 411, 313-316.	2.8	64
36	Sensitized Detection of Inhibitory Fragments and Iterative Development of Non-Peptidic Protease Inhibitors by Dynamic Ligation Screening. <i>Angewandte Chemie - International Edition</i> , 2008, 47, 3275-3278.	13.8	64

#	ARTICLE	IF	CITATIONS
37	<scp>RNA</scp>â€virus proteases counteracting host innate immunity. FEBS Letters, 2017, 591, 3190-3210.	2.8	64
38	Development and Characterization of New Peptidomimetic Inhibitors of the West Nile Virus NS2Bâ€NS3 Protease. ChemMedChem, 2013, 8, 231-241.	3.2	63
39	The Capsid Binder Vapendavir and the Novel Protease Inhibitor SC85 Inhibit Enterovirus 71 Replication. Antimicrobial Agents and Chemotherapy, 2014, 58, 6990-6992.	3.2	60
40	Liberation of SARS-CoV main protease from the viral polyprotein: N-terminal autocleavage does not depend on the mature dimerization mode. Protein and Cell, 2010, 1, 59-74.	11.0	58
41	Crystal Structure of the Peroxo-diiron(III) Intermediate of Deoxyhypusine Hydroxylase, an Oxygenase Involved in Hypusination. Structure, 2015, 23, 882-892.	3.3	55
42	Extended substrate specificity and first potent irreversible inhibitor/activity-based probe design for Zika virus NS2B-NS3 protease. Antiviral Research, 2017, 139, 88-94.	4.1	55
43	Antiviral Activity of Broad-Spectrum and Enterovirus-Specific Inhibitors against Clinical Isolates of Enterovirus D68. Antimicrobial Agents and Chemotherapy, 2015, 59, 7782-7785.	3.2	54
44	Binding of phenol to R6 insulin hexamers*. Biopolymers, 1999, 51, 165-172.	2.4	52
45	Thiazolidone derivatives as inhibitors of chikungunya virus. European Journal of Medicinal Chemistry, 2015, 89, 172-178.	5.5	52
46	Zika virus <scp>NS</scp>1, a pathogenicity factor with many faces. EMBO Journal, 2016, 35, 2631-2633.	7.8	52
47	Design, Synthesis, and Biological Evaluation of Peptidomimetic Aldehydes as Broad-Spectrum Inhibitors against Enterovirus and SARS-CoV-2. Journal of Medicinal Chemistry, 2022, 65, 2794-2808.	6.4	52
48	An Efficient Method for the Synthesis of Peptide Aldehyde Libraries Employed in the Discovery of Reversible SARS Coronavirus Main Protease (SARSâ€CoV M pro) Inhibitors. ChemBioChem, 2006, 7, 1048-1055.	2.6	50
49	Recent Advances in Targeting Viral Proteases for the Discovery of Novel Antivirals. Current Topics in Medicinal Chemistry, 2010, 10, 323-345.	2.1	48
50	Variable Oligomerization Modes in Coronavirus Non-structural Protein 9. Journal of Molecular Biology, 2008, 383, 1081-1096.	4.2	47
51	The â€SARS-unique domainâ€(SUD) of SARS coronavirus is an oligo(G)-binding protein. Biochemical and Biophysical Research Communications, 2007, 364, 877-882.	2.1	46
52	An overview on 2-methyl-2,4-pentanediol in crystallization and in crystals of biological macromolecules. Acta Crystallographica Section D: Biological Crystallography, 2002, 58, 1722-1728.	2.5	43
53	Virusâ€host interactomes â€ antiviral drug discovery. Current Opinion in Virology, 2012, 2, 614-621.	5.4	40
54	The non-structural protein Nsp10 of mouse hepatitis virus binds zinc ions and nucleic acids. FEBS Letters, 2006, 580, 4143-4149.	2.8	36

#	ARTICLE	IF	CITATIONS
55	Crystal structures of the X ¹ and X ³ domains of a Group 1 and a Group 3 coronavirus reveal that ADP-ribose-binding may not be a conserved property. <i>Protein Science</i> , 2009, 18, 6-16.	7.6	36
56	Effects of NS2B-NS3 protease and furin inhibition on West Nile and Dengue virus replication. <i>Journal of Enzyme Inhibition and Medicinal Chemistry</i> , 2017, 32, 712-721.	5.2	34
57	WaaA of the Hyperthermophilic Bacterium <i>Aquifex aeolicus</i> Is a Monofunctional 3-Deoxy-d-manno-oct-2-ulosonic Acid Transferase Involved in Lipopolysaccharide Biosynthesis. <i>Journal of Biological Chemistry</i> , 2009, 284, 22248-22262.	3.4	33
58	Calcium Binding of Transglutaminases: A ⁴³ Ca NMR Study Combined with Surface Polarity Analysis. <i>Journal of Biomolecular Structure and Dynamics</i> , 2001, 19, 59-74.	3.5	32
59	How do the GTPases really work?. <i>Nature Structural Biology</i> , 1995, 2, 3-6.	9.7	31
60	Irreversible inhibitors of the 3C protease of Coxsackie virus through templated assembly of protein-binding fragments. <i>Nature Communications</i> , 2016, 7, 12761.	12.8	30
61	Structural and mutational analysis of the interaction between the Middle-East respiratory syndrome coronavirus (MERS-CoV) papain-like protease and human ubiquitin. <i>Virologica Sinica</i> , 2016, 31, 288-299.	3.0	30
62	The Structure of the Zika Virus Protease, NS2B/NS3pro. <i>Advances in Experimental Medicine and Biology</i> , 2018, 1062, 131-145.	1.6	28
63	The SARS-CoV-2 unique domain (SUD) of SARS-CoV and SARS-CoV-2 interacts with human Paip1 to enhance viral RNA translation. <i>EMBO Journal</i> , 2021, 40, e102277.	7.8	26
64	Structure of the GTPase and GDI domains of FeoB, the ferrous iron transporter of <i>Legionella pneumophila</i> . <i>FEBS Letters</i> , 2010, 584, 733-738.	2.8	25
65	Coronavirus main proteinase: target for antiviral drug therapy. , 2005, , 173-199.		20
66	Acquisition of new protein domains by coronaviruses: analysis of overlapping genes coding for proteins N and 9b in SARS coronavirus. <i>Virus Genes</i> , 2015, 50, 29-38.	1.6	20
67	Structural biology in the fight against COVID-19. <i>Nature Structural and Molecular Biology</i> , 2021, 28, 2-7.	8.2	20
68	Structures of DegQ from <i>Legionella pneumophila</i> Define Distinct ON and OFF States. <i>Journal of Molecular Biology</i> , 2015, 427, 2840-2851.	4.2	19
69	The Enterovirus 3C Protease Inhibitor SG85 Efficiently Blocks Rhinovirus Replication and Is Not Cross-Resistant with Rupintrivir. <i>Antimicrobial Agents and Chemotherapy</i> , 2015, 59, 5814-5818.	3.2	18
70	Viral enzymes. <i>Current Opinion in Structural Biology</i> , 2006, 16, 776-786.	5.7	17
71	Application of a cell-based protease assay for testing inhibitors of picornavirus 3C proteases. <i>Antiviral Research</i> , 2014, 103, 17-24.	4.1	17
72	Structure of the X (ADRP) domain of nsp3 from feline coronavirus. <i>Acta Crystallographica Section D: Biological Crystallography</i> , 2009, 65, 1292-1300.	2.5	16

#	ARTICLE	IF	CITATIONS
73	Profiling of flaviviral NS2B-NS3 protease specificity provides a structural basis for the development of selective chemical tools that differentiate Dengue from Zika and West Nile viruses. <i>Antiviral Research</i> , 2020, 175, 104731.	4.1	14
74	A method to detect nonprolinecis peptide bonds in proteins. <i>Biopolymers</i> , 1999, 50, 536-544.	2.4	13
75	Lybatides from <i>Lycium barbarum</i> Contain An Unusual Cystine-stapled Helical Peptide Scaffold. <i>Scientific Reports</i> , 2017, 7, 5194.	3.3	13
76	Structure and Dynamics of Sars Coronavirus Main Proteinase (MPRO). <i>Advances in Experimental Medicine and Biology</i> , 2006, 581, 585-591.	1.6	12
77	Coxsackievirus B3 protease 3C: expression, purification, crystallization and preliminary structural insights. <i>Acta Crystallographica Section F, Structural Biology Communications</i> , 2016, 72, 877-884.	0.8	11
78	Crystal structure of the C-terminal fragment of NS1 protein from yellow fever virus. <i>Science China Life Sciences</i> , 2017, 60, 1403-1406.	4.9	11
79	From Repurposing to Redesign: Optimization of Boceprevir to Highly Potent Inhibitors of the SARS-CoV-2 Main Protease. <i>Molecules</i> , 2022, 27, 4292.	3.8	10
80	Perspectives on Single Molecule Diffraction Using the X-Ray Free Electron Laser. <i>Single Molecules</i> , 2002, 3, 63-68.	0.9	9
81	Structural Basis of the Proteolytic and Chaperone Activity of <i>Chlamydia trachomatis</i> CT441. <i>Journal of Bacteriology</i> , 2015, 197, 211-218.	2.2	9
82	Insights into the GTPase Mechanism of EF-Tu from Structural Studies. , 0, , 347-357.		7
83	STD-NMR experiments identify a structural motif with novel second-site activity against West Nile virus NS2B-NS3 protease. <i>Antiviral Research</i> , 2017, 146, 174-183.	4.1	6
84	Crystal structure of the middle domain of human poly(A)-binding protein-interacting protein 1. <i>Biochemical and Biophysical Research Communications</i> , 2011, 408, 680-685.	2.1	5
85	Sometimes Intermediates Do the Job!. <i>Chemistry and Biology</i> , 2006, 13, 235-236.	6.0	4
86	Viral Entry and NS1 as Potential Antiviral Drug Targets. <i>Advances in Experimental Medicine and Biology</i> , 2018, 1062, 107-113.	1.6	4
87	Structural Proteomics of Emerging Viruses: The Examples of SARS-CoV and Other Coronaviruses. , 2008, , 361-433.		4
88	Computer-Aided Structure Based Drug Design Approaches for the Discovery of New Anti-CHIKV Agents. <i>Current Computer-Aided Drug Design</i> , 2017, 13, 346-361.	1.2	4
89	Synthesis, Structure-Activity Relationships, and Antiviral Profiling of 1-Heteroaryl-2-Alkoxyphenyl Analogs as Inhibitors of SARS-CoV-2 Replication. <i>Molecules</i> , 2022, 27, 1052.	3.8	4
90	Characterization of an Allosteric Pocket in Zika Virus NS2B-NS3 Protease. <i>Journal of Chemical Information and Modeling</i> , 2022, 62, 945-957.	5.4	4

#	ARTICLE	IF	CITATIONS
91	Structure-based antivirals for emerging and neglected RNA viruses: an emerging field for medicinal chemistry in academia. <i>Future Medicinal Chemistry</i> , 2010, 2, 1061-1067.	2.3	3
92	Third Tofo Advanced Study Week on Emerging and Re-emerging Viruses, 2018. <i>Antiviral Research</i> , 2019, 162, 142-150.	4.1	3
93	Identification of non-covalent SARS-CoV-2 main protease inhibitors by a virtual screen of commercially available drug-like compounds. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2021, 41, 127990.	2.2	2
94	Non Structural Proteins 8 and 9 of Human Coronavirus 229E. <i>Advances in Experimental Medicine and Biology</i> , 2006, 581, 49-54.	1.6	2
95	Production, crystallization and X-ray diffraction analysis of the protease CT441 from <i>Chlamydia trachomatis</i> . <i>Acta Crystallographica Section F, Structural Biology Communications</i> , 2015, 71, 1454-1458.	0.8	1
96	Production of Coronavirus Nonstructural Proteins in Soluble Form for Crystallization. <i>Methods in Molecular Biology</i> , 2008, 454, 139-159.	0.9	1